Synopsis:
Jenburkt Pharmaceuticals Limited, a Pharma Stock, reports 28.27% QoQ revenue growth and a 30.42% QoQ net profit surge in Q2 FY26 results.
This micro-cap pharma stock, engaged in manufacturing, producing, developing, and marketing pharmaceutical formulations, including prescription medications and healthcare products, across India, jumped 10.19 percent after the company reported September quarterly results with a 30.42 percent QoQ increase in net profit.
With a market capitalization of Rs. 498.81 crores, the share of Jenburkt Pharmaceuticals Limited has reached an intraday high of Rs. 1,175 per equity share, rising nearly 10.19 percent from its previous day’s close price of Rs. 1,066.35. Since then, the stock has retreated and is currently trading at Rs. 1,130.25 per equity share.
Q2 FY26 Result Walkthrough
Coming into the quarterly results of Jenburkt Pharmaceuticals Limited, the company’s consolidated revenue from operations increased by 10.56 percent YOY, from Rs. 41.21 crore in Q2 FY25 to Rs. 45.56 crore in Q2 FY26, and grew by 28.27 percent QoQ from Rs. 35.52 crore in Q1 FY26.
In Q2 FY26, Jenburkt Pharmaceuticals Limited’s consolidated net profit increased by 5.83 percent YOY, reaching Rs. 10.16 crore compared to Rs. 9.60 crore during the same period last year. As compared to Q1 FY26, the net profit has increased by 30.42 percent, from Rs. 7.79 crore.
The basic earnings per share increased by 5.89 percent and stood at Rs. 23.03 as against Rs. 21.75 recorded in the same quarter in the previous year, FY2025. Jenburkt Pharmaceuticals Limited’s revenue and net profit have grown at a CAGR of 5.02 percent and 16.36 percent, respectively, over the last five years.
In terms of return ratios, the company’s ROCE and ROE stand at 27.2 percent and 19.9 percent, respectively. Jenburkt Pharmaceuticals Limited has an earnings per share (EPS) of Rs. 74.8, and its debt-to-equity ratio is 0.01x.
Company Overview
Jenburkt Pharmaceuticals Limited was founded in 1985 and is a Mumbai-based pharmaceutical company with a presence spanning 13 countries, employing over 850 team members. The company has grown from a family business into a trusted organization focused on delivering excellence in life sciences through innovative healthcare solutions.
The company is engaged in the manufacturing, development, and marketing of pharmaceutical formulations and healthcare products. Jenburkt serves a wide range of therapeutic areas, including pain management, analgesics, muscle relaxants, nutraceuticals, anti-infectives, anti-diabetics, and consumer healthcare products.
Jenburkt Pharmaceuticals offers various branded products such as Allerzine, CartiSafe Forte, Frendacid, GLUCOTROL, Jenflam, and Powergesic, among others. The company conducts export operations to approximately 13 countries around the world.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
